Expression and activation of the farnesoid X receptor in the vasculature.
about
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and CancerThe bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in miceBile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytesBile acid signaling in metabolic disease and drug therapyNutritional lipidomics: molecular metabolism, analytics, and diagnosticsFXR-mediated regulation of eNOS expression in vascular endothelial cellsFarnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulationFXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9.Farnesoid X receptor deletion improves cardiac function, structure and remodeling following myocardial infarction in miceOxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor.Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.Effects of deoxycholylglycine, a conjugated secondary bile acid, on myogenic tone and agonist-induced contraction in rat resistance arteriesDisruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration.Deciphering the nuclear bile acid receptor FXR paradigm.Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion.Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discoveryIncreased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cellsExpression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.Effects of FXR in foam-cell formation and atherosclerosis development.FXR protects lung from lipopolysaccharide-induced acute injuryPregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.Upregulation of decorin by FXR in vascular smooth muscle cells.Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspectiveCardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury.Bile acids regulate cardiovascular functionFXR signaling in metabolic disease.FXR an emerging therapeutic target for the treatment of atherosclerosisGuggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products.Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginineFarnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease.Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice.A little humour relaxes the gallbladder.Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome.Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling?Bile acid receptors as targets for drug development.Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer.
P2860
Q26800206-4D9B395C-2F2A-4149-BA2B-4D0505F6FE0EQ27318414-3D1B4B9B-1E1A-4AD1-871B-090BDF5D16D1Q27332942-CDA903BE-7130-495E-9D5C-831B74338E66Q28244875-4387475C-8A99-46F0-ACC0-ABF7E063AA69Q28390150-0F97BD5B-B5AF-4C56-B5F4-3F43987F0E73Q28572543-DDA58069-4DA7-4B1B-9A56-2393BB60737FQ28581627-A8C5BF82-ED46-4078-B213-4607D359AA48Q30488268-0AEF8D51-9F27-44F4-80AA-2E51283B44FFQ33828171-96E2057E-F2A6-4531-B872-2333895D8CDAQ33967334-990CE864-1595-4FC4-952A-FBA10ED757F0Q34019132-70DA7B9F-BE3B-4248-8ABB-FD68FB401999Q34168512-EE8C8606-8EA2-40EF-8023-8412D2C2A6C3Q34577470-10114BB9-E5AE-44BD-87E9-ACD32FC0802AQ34626518-3E6C41EC-2F2E-4CE8-9247-99832BCACACFQ34727267-A7D3DE5D-B917-44CF-B110-59E4BA923313Q34729209-0501AB4C-0771-4589-A183-F85DD2D319BDQ35085053-C3FA6587-9344-45B9-8F9F-F89E89502AC3Q35110744-CE2E3C84-1830-4462-80C3-40EA67CBBE1DQ35546179-CA170E0B-95AE-40F2-9F0E-8FE0C675E11CQ35640697-7E959C48-A01B-48EB-B70B-8B93C4ABCF13Q35792726-D24CE1E1-3D30-4CFB-84B6-4D898B2E1EC8Q36145170-34BB9A12-1819-4EED-8F19-55EEB2209B0BQ36598778-47B13A68-7695-439A-A701-109198BDF282Q36853007-B2D0A5A7-15FC-445C-BDAB-88B51DDFCDEEQ36931713-5A06FEEB-D37D-4BCF-990A-F419962E9650Q36945630-53830A4A-08D3-4832-8032-BE3993C9BB94Q36995617-674749F0-7B96-41A7-A71B-89D6DAF02BF9Q37006382-9B57CBCF-F771-454E-AAF9-832646550791Q37334984-0BCD43A9-98D1-4024-819C-7B2976AC2205Q37346998-F5A9FC2A-F81B-4E58-9549-B334625EDFD0Q37397252-D1FC02CA-808A-4DD2-AE5B-17FF878A1871Q37485728-1A425D00-2794-4B09-A3D1-60976C86EBABQ37528259-6527094A-8AE9-4D37-B65B-198466544296Q37587745-7CF762F6-E804-424F-9372-63ADD56CA4E2Q37784591-E60647C5-B575-4957-B9BC-7ED841535894Q37900938-95AA1E54-8AE0-4595-A6AC-30032809E63DQ38095223-20E2DB61-1C2B-4E2F-80BB-8F95215D7051Q38115716-097DBD3C-3133-495C-BCB0-0287195F7631Q38132058-EC91B2FB-7B3B-441E-A092-805D5EAAF38DQ38161329-7F374109-D0FC-4139-8482-F775A9088347
P2860
Expression and activation of the farnesoid X receptor in the vasculature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 February 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Expression and activation of the farnesoid X receptor in the vasculature.
@en
Expression and activation of the farnesoid X receptor in the vasculature.
@nl
type
label
Expression and activation of the farnesoid X receptor in the vasculature.
@en
Expression and activation of the farnesoid X receptor in the vasculature.
@nl
prefLabel
Expression and activation of the farnesoid X receptor in the vasculature.
@en
Expression and activation of the farnesoid X receptor in the vasculature.
@nl
P2860
P356
P1476
Expression and activation of the farnesoid X receptor in the vasculature.
@en
P2093
David Bishop-Bailey
Desmond T Walsh
P2860
P304
P356
10.1073/PNAS.0400046101
P407
P577
2004-02-27T00:00:00Z